Sign in
PEPG Stock Price, Chart, Stats & News
PepGen Ltd
Save
PepGen Ltd (PEPG) does not currently pay a dividend.
168.77M
Market cap
–
Current P/E
–
Forward P/E
PEPG chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.05% |
ROA | -51.55% |
ROE | -75.73% |
D/E | 0.12x |
Interest coverage ratio | – |
PEPG valuation
P/E | – |
P/S | – |
P/B | 1.29x |
P/CF | -2.34x |
P/FCF | -3.81x |
P/OCF | -2.34x |
PEG | -0.15x |
EV multiple | -3.86x |
About
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study.
Similar securities
Based on sector and market capitalization
Report issue